MedTrace Logo

Safety and Efficacy of JMKX000189 for Chemotherapy-Induced Peripheral Neuropathy

NCT07601386 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-05-22

No results posted yet for this study

Summary

This Phase Ib clinical trial aims to evaluate the safety, tolerability, and preliminary efficacy of JMKX000189 tablets in participants with chemotherapy-induced peripheral neuropathy (CIPN).

Conditions

  • CIPN - Chemotherapy-Induced Peripheral Neuropathy

Interventions

DRUG

JMKX000189

JMKX000189 administered orally.

OTHER

Placebo

Placebo administered orally.

Sponsors & Collaborators

  • Shanghai Jeyou Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Ruofan Huang · Huashan Hospital

  • Xiaojie Wu · Huashan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-10
Primary Completion
2027-06-20
Completion
2027-06-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07601386 on ClinicalTrials.gov